Cited by 595Liver physiology and pathologyLiver Disease Diagnosis and TreatmentLiver Disease and Transplantation

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Open access

Zhang, Chong-Yang, Yuan, Wei-Gang, He, Pei, Lei, Jia-Hui, Wang, Chun-Xu·2016·World Journal of Gastroenterology

DOI 10.3748/wjg.v22.i48.10512PMC PMC5192262

Open this paper in CoChat — free account Open PDF

Abstract

Liver fibrosis is a reversible wound-healing process aimed at maintaining organ integrity, and presents as the critical pre-stage of liver cirrhosis, which will eventually progress to hepatocellular carcinoma in the absence of liver transplantation.Fibrosis generally results from chronic hepatic injury caused by various factors, mainly viral infection, schistosomiasis, and alcoholism; however, the exact pathological mechanisms are still unknown.Although numerous drugs have been shown to have antifibrotic activity in vitro and in animal models, none of these drugs have been shown to be efficacious in the clinic.Importantly, hepatic stellate cells (HSCs) play a key role in the initiation, progression, and regression of liver fibrosis by secreting fibrogenic factors that encourage portal fibrocytes, fibroblasts, and bone marrow-derived myofibroblasts to produce collagen and thereby propagate fibrosis.These cells are subject to intricate cross-talk with adjacent cells, resulting in scarring and subsequent liver damage.Thus, an understanding of the molecular mechanisms of liver fibrosis and their relationships with HSCs is essential for the discovery of new therapeutic targets.This comprehensive review outlines the role of HSCs in liver fibrosis and details novel strategies to suppress HSC activity, thereby providing new insights into potential treatments for liver fibrosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3748/wjg.v22.i48.10512

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Initiation, progression, and resolution of liver fibrosis involving hepatic stellate cells. Upon various types of chronic injury - including that caused by alcohol, viral and schistosome infection, nonalcoholic steatohepatitis (NASH), and other factors - hepatic stellate cells (HSCs) transdifferentiate from quiescent HSCs to activated HSCs, the latter of which secrete abundant extracellular proteins that contribute to liver fibrosis. Liver fibrosis is thought to be a reversible condition owing to the elimination of causative agents and different strategies of limiting HSC activation; however, they cannot totally return to a quiescent status of the naive HSCs. Instead, they exhibit a pre-activated intermediate condition with an increased sensitivity to injury. Thus, preventing recurrent chronic liver injury is of great importance in patients undergoing treatment for liver fibrosis. Untreated or relapsed fibrosis progresses to liver cirrhosis, which often requires hepatic transplantation.CC BY-NC · PubMed Central

Figure 2 Roles of interleukin-30, hydrogen peroxide inducible clone 5, and cholesterol acyltransferase 1 in liver fibrosis.CC BY-NC · PubMed Central

Figure 3 Roles of the Wnt, TGF-β/Smad, and Gas6/Axl signaling pathways in the progression of liver fibrosis.CC BY-NC · PubMed Central

Figure 4 Mechanism of action of three potential therapeutic drugs-ursolic acid, 24-nor-ursodeoxycholic acid, and resveratrol-for treating fibrosis.CC BY-NC · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The burden of liver disease in Europe: A review of available epidemiological data
Blachier, M., Leleu, H., Peck‐Radosavljevic, M., Valla, D. C., & Roudot‐Thoraval, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.005 · Cited by 1,340
The natural history of nonalcoholic fatty liver: A follow-up study
Teli, M. R., James, O., Burt, A. D., Bennett, M. K., & Day, C. P. (1995) · Hepatology · doi:10.1002/hep.1840220616 · Cited by 913
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway
Feldstein, A. E., Werneburg, N. W., Canbay, A. E., Guicciardi, M. E., Bronk, S. F., Rydzewski, R. M., Burgart, L. J., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20283 · Cited by 851
CYP2E1 and oxidative liver injury by alcohol
Lu, Y., & Cederbaum, A. I. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.11.004 · Cited by 805
Hepatic fibrosis: concept to treatment
Trautwein, C., Friedman, S. L., Schuppan, D., & Pinzani, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.039 · Cited by 677
AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol
Um, J.-H., Park, S.-J., Kang, H., Yang, S., Foretz, M., McBurney, M. W., Kim, M. K., Viollet, B., & Chung, J. H. (2010) · Diabetes · doi:10.2337/db09-0482 · Cited by 647

Show all 112 references

Research works printed but not linked: 1

10.1002/cphy.c120035 · DOI · Paper page

Sorted by citations

Wound healing, fibroblast heterogeneity, and fibrosis
desJardins-Park, H. E., Mascharak, S., Griffin, M., Wan, D. C., & Longaker, M. T. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.07.006 · Cited by 835
Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Dilliard, S. A., & Siegwart, D. J. (2023) · Nature Reviews Materials · doi:10.1038/s41578-022-00529-7 · Cited by 744
Liver fibrosis
Aydin, M. M., & Akçalı, K. C. (2018) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2018.17330 · Cited by 397
The double edge sword of fibrosis in cancer
Chandler, C., Liu, T., Buckanovich, R. J., & Coffman, L. G. (2019) · Translational research · doi:10.1016/j.trsl.2019.02.006 · Cited by 257
RETRACTED ARTICLE: A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine
Moghadasi, S., Elveny, M., Rahman, H. S., Suksatan, W., Jalil, A. T., Abdelbasset, W. K., Yumashev, A. V., Shariatzadeh, S., Motavalli, R., Behzad, F., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02980-6 · Cited by 207
Retracted
Understanding Nanomaterial–Liver Interactions to Facilitate the Development of Safer Nanoapplications
Li, J., Chen, C., & Xia, T. (2022) · Advanced Materials · doi:10.1002/adma.202106456 · Cited by 172
A human multi-lineage hepatic organoid model for liver fibrosis
Guan, Y., Enejder, A., Wang, M., Fang, Z., Cui, L., Chen, S.-Y., Wang, J., Tan, Y., Wu, M., Chen, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26410-9 · Cited by 149
Extensive Summary of the Important Roles of Indole Propionic Acid, a Gut Microbial Metabolite in Host Health and Disease
Jiang, H., Chen, C., & Gao, J. (2022) · Nutrients · doi:10.3390/nu15010151 · Cited by 153
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
‘Magnesium’-the master cation-as a drug—possibilities and evidences
Mathew, A. A., & Panonnummal, R. (2021) · BioMetals · doi:10.1007/s10534-021-00328-7 · Cited by 131
In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications
Ramos, M. J., Bandiera, L., Menolascina, F., & Fallowfield, J. A. (2022) · iScience · doi:10.1016/j.isci.2021.103549 · Cited by 127
Regulation of cellular senescence by extracellular matrix during chronic fibrotic diseases
Blokland, K. E. C., Pouwels, S. D., Schuliga, M. J., Knight, D. A., & Burgess, J. K. (2020) · Clinical Science · doi:10.1042/cs20190893 · Cited by 132
Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways
Cheng, Q., Li, C., Yang, C., Zhong, Y., Wu, D., Shi, L., Chen, L., Li, Y., & Li, L. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.12.006 · Cited by 126
Emerging Roles of Lipophagy in Health and Disease
Kounakis, K., Chaniotakis, M., Markaki, M., & Tavernarakis, N. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00185 · Cited by 129
Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Lee, C., Kim, J., & Jung, Y. (2019) · Cells · doi:10.3390/cells8101259 · Cited by 128
Adoptive Transfer of Bone Marrow-Derived Monocytes Ameliorates Schistosoma mansoni -Induced Liver Fibrosis in Mice
de Souza, V. C. A., Moura, D. M. N., de Castro, M. C. A. B., Bozza, P. T., Paiva, L. A., Fernandes, C. J. B., Leão, R. L. C., Lucena, J. P., de Araújo, R. E., Silva, A. J. D. M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42703-y · Cited by 116
Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
Torre, S. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572490 · Cited by 125
MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization
Zhang, J., Liu, Y., Chen, H., Yuan, Q., Wang, J., Niu, M., Hou, L., Gu, J., & Zhang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04802-z · Cited by 116
Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy
Fan, Q.-Q., Zhang, C.-L., Qiao, J.-B., Cui, P.-F., Xing, L., Oh, Y.-K., & Jiang, H.-L. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119616 · Cited by 111
Self-citation
Mesenchymal stem cell-originated exosomal circDIDO1 suppresses hepatic stellate cell activation by miR-141-3p/PTEN/AKT pathway in human liver fibrosis
Ma, L., Wei, J., Zeng, Y., Liu, J., Xiao, E., Kang, Y., & Kang, Y. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2030428 · Cited by 109
Macrophage in liver Fibrosis: Identities and mechanisms
Wang, Z., Du, K., Jin, N., Tang, B., & Zhang, W. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110357 · Cited by 119
TRIM26 Induces Ferroptosis to Inhibit Hepatic Stellate Cell Activation and Mitigate Liver Fibrosis Through Mediating SLC7A11 Ubiquitination
Zhu, Y., Zhang, C., Huang, M., Lin, J., Fan, X. M., & Ni, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.644901 · Cited by 103
Self-citation
T lymphocytes as critical mediators in tissue regeneration, fibrosis, and the foreign body response
Adusei, K. M., Ngo, T. B., & Sadtler, K. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.023 · Cited by 102
Esculin inhibits hepatic stellate cell activation and CCl4-induced liver fibrosis by activating the Nrf2/GPX4 signaling pathway.
Xu, S.-X., Chen, Y.-E., Miao, J., Li, Y.-H., Liu, J., Zhang, J., Liang, J., Chen, S.-X., & Hou, S.-Z. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155465 · Cited by 101
Biological characteristics of exosomes and genetically engineered exosomes for the targeted delivery of therapeutic agents
Yan, L., Lu, Y., & Li, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1641508 · Cited by 99
Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention
O’Gorman, P., Naimimohasses, S., Monaghan, A., Kennedy, M., Melo, A. M., Ní Fhloinn, D., Doherty, D. G., Beddy, P., Finn, S. P., Moore, J. B., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15989 · Cited by 94
Iron regulatory protein 2 is required for artemether -mediated anti-hepatic fibrosis through ferroptosis pathway
Li, Y., Jin, C., Shen, M., Wang, Z., Tan, S., Chen, A., Wang, S., Shao, J., Zhang, F., Zhang, Z., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.09.008 · Cited by 89
Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology
Torre, S. D. (2021) · Cells · doi:10.3390/cells10092502 · Cited by 91
Pyruvate Kinase M2 Tetramerization Protects against Hepatic Stellate Cell Activation and Liver Fibrosis
Zheng, D., Jiang, Y., Qu, C., Yuan, H., Hu, K., He, L., Chen, P., Li, J., Tu, M., Lin, L., et al. (2020) · American Journal Of Pathology · doi:10.1016/j.ajpath.2020.08.002 · Cited by 88
Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis
Lee, J., Byun, J., Shim, G., & Oh, Y.-K. (2022) · Nature Communications · doi:10.1038/s41467-022-29186-8 · Cited by 79
Umbelliferone Ameliorates CCl4-Induced Liver Fibrosis in Rats by Upregulating PPARγ and Attenuating Oxidative Stress, Inflammation, and TGF-β1/Smad3 Signaling
Mahmoud, A. M., Hozayen, W. G., Hasan, I. H., Shaban, E., & Bin-Jumah, M. N. (2019) · Inflammation · doi:10.1007/s10753-019-00973-8 · Cited by 78
Programmed cell death in hepatic fibrosis: current and perspectives
Lu, J.-L., Yu, C.-X., & Song, L.-J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01749-8 · Cited by 81
Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease
Wu, D., Wang, D., Li, H., Guo, J., Duan, S., & Ji, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3831713 · Cited by 75
Novel Insights on Notch signaling pathways in liver fibrosis
Ni, M.-M., Wang, Y.-R., Wu, W., Xia, C.-C., Zhang, Y.-H., Xu, J., Xu, T., & Li, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.051 · Cited by 73
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 71
The Role of S1P and the Related Signaling Pathway in the Development of Tissue Fibrosis
Wang, E., He, X., & Zeng, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01504 · Cited by 70
PPARγ/NF‐κB and TGF‐β1/Smad pathway are involved in the anti‐fibrotic effects of levo‐tetrahydropalmatine on liver fibrosis
Yu, Q., Cheng, P., Wu, J., & Guo, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16267 · Cited by 68
Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases
Mooli, R. G. R., Mukhi, D., & Ramakrishnan, S. K. (2022) · Comprehensive physiology · doi:10.1002/cphy.c200021 · Cited by 134
Eosinophils and Macrophages within the Th2-Induced Granuloma: Balancing Killing and Healing in a Tight Space
Ariyaratne, A., & Finney, C. A. M. (2019) · Infection and Immunity · doi:10.1128/iai.00127-19 · Cited by 68
Matrix metalloproteinase-1 decorated polymersomes, a surface-active extracellular matrix therapeutic, potentiates collagen degradation and attenuates early liver fibrosis
Geervliet, E., Moreno, S., Baiamonte, L., Booijink, R. S., Boye, S., Wang, P., Voit, B. I., Lederer, A., Appelhans, D., & Bansal, R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.016 · Cited by 65
Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma
Ali, N. A., Hamdy, N. Μ., Gibriel, A. A., & EL-Mesallamy, H. O. (2021) · Archives of Virology · doi:10.1007/s00705-021-04981-8 · Cited by 64
Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease
Bukke, V. N., Moola, A., Serviddio, G., Vendemiale, G., & Bellanti, F. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i48.6909 · Cited by 69
Foxp3+ Regulatory T Cells Inhibit CCl4-Induced Liver Inflammation and Fibrosis by Regulating Tissue Cellular Immunity
Ikeno, Y., Ohara, D., Takeuchi, Y., Watanabe, H., Kondoh, G., Taura, K., Uemoto, S., & Hirota, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584048 · Cited by 62
Lipids associated with autophagy: mechanisms and therapeutic targets
Jarocki, M., Turek, K., Saczko, J., Tarek, M., & Kulbacka, J. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02224-8 · Cited by 68
Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver Fibrosis
Milito, A., Brancaccio, M., D’Argenio, G., & Castellano, I. (2019) · Cells · doi:10.3390/cells8111356 · Cited by 62
Bone morphogenetic protein-7 represses hepatic stellate cell activation and liver fibrosis via regulation of TGF-β/Smad signaling pathway
Zou, G.-L., Zuo, S., Lu, S., Hu, R.-H., Lu, Y.-F., Yang, J., Deng, K.-S., Wu, Y.-T., Mu, M., Zhu, J.-J., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i30.4222 · Cited by 50
Albumin-Based Silibinin Nanocrystals Targeting Activated Hepatic Stellate Cells for Liver Fibrosis Therapy
Luo, S., Yang, Y., Zhao, T., Zhang, R., Fang, C., Li, Y., Zhang, Z., & Gong, T. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19269 · Cited by 63
Liver fibrosis: the 2017 state of art
Caviglia, G. P., Rosso, C., Fagoonee, S., Saracco, G. M., & Pellicano, R. (2017) · Panminerva Medica · doi:10.23736/s0031-0808.17.03359-6 · Cited by 62
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
Sharip, A., & Kunz, J. (2025) · Cells · doi:10.3390/cells14040266 · Cited by 63
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Frankowski, R., Kobierecki, M., Wittczak, A., Różycka-Kosmalska, M., Pietras, T., Sipowicz, K., & Kosmalski, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119677 · Cited by 58
The Space of Disse: The Liver Hub in Health and Disease
Sanz-García, C., Fernández-Iglesias, A., Gracia-Sancho, J., Arráez-Aybar, L. A., Nevzorova, Y. A., & Cubero, F. J. (2021) · Livers · doi:10.3390/livers1010002 · Cited by 57
Hepatic Stellate Cell: A Double-Edged Sword in the Liver
Luo, N., Li, J., Wei, Y., Lu, J., & Dong, R. (2021) · Physiological Research · doi:10.33549/physiolres.934755 · Cited by 64
Human umbilical cord mesenchymal stem cells ameliorate liver fibrosisin vitroandin vivo: From biological characteristics to therapeutic mechanisms
Yin, F., Wang, W., & Jiang, W. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i8.548 · Cited by 57
Neovascularization is a key feature of liver fibrosis progression: anti-angiogenesis as an innovative way of liver fibrosis treatment
Zadorozhna, M., Gioia, S. D., Conese, M., & Mangieri, D. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05290-0 · Cited by 60
Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats
Thakur, R., Sharma, A., Lingaraju, M. C., Begum, J., Kumar, D., Karikalan, M., Kumar, P., Singh, T. U., & Kumar, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.143 · Cited by 56
Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury
Du, K., Oh, S., Dutta, R. K., Sun, T., Yang, W., Chi, J., & Diehl, A. M. (2021) · Liver International · doi:10.1111/liv.14945 · Cited by 61
Liver-on-a-chip devices: the pros and cons of complexity
Dalsbecker, P., Adiels, C. B., & Goksör, M. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00346.2021 · Cited by 56
Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming
Lu, J. Y., Tu, W. B., Li, R., Weng, M., Sanketi, B. D., Yuan, B., Reddy, P., Rodriguez Esteban, C., & Izpisua Belmonte, J. C. (2025) · Cell · doi:10.1016/j.cell.2025.07.031 · Cited by 68
Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update
Duspara, K., Bojanic, K., Pejic, J. I., Kuna, L., Kolarić, T. O., Nincevic, V., Smolić, R., Vcev, A., Glasnovic, M., Curcic, I. B., et al. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00065 · Cited by 60
Human Liver Regeneration: An Etiology Dependent Process
Haele, M. V., Snoeck, J., & Roskams, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092332 · Cited by 55
Novel Strategy for Validating the Existence and Mechanism of the “Gut–Liver Axis” in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe
Tian, Y., Li, Y., Wang, W., Jiang, W., Fei, J., & Li, C. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04578 · Cited by 53
Glutathione Might Attenuate Cadmium-Induced Liver Oxidative Stress and Hepatic Stellate Cell Activation
Ren, L., Qi, K., Zhang, L., Bai, Z., Ren, C., Xu, X.-Y., Zhang, Z., & Li, X. (2019) · Biological Trace Element Research · doi:10.1007/s12011-019-1641-x · Cited by 51
Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway
Riaz, F., Chen, Q., Lu, K., Osoro, E. K., Wu, L., Feng, L., Zhao, R., Yang, L., Zhou, Y., He, Y., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16376 · Cited by 52
Drug delivery of pH-Sensitive nanoparticles into the liver cancer cells
Saadat, M., Mostafaei, F., Mahdinloo, S., Abdi, M., Zahednezhad, F., Zakeri‐Milani, P., & Valizadeh, H. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102557 · Cited by 53
Wnt/beta‐catenin signaling and its modulators in nonalcoholic fatty liver diseases
Harini, K. S., & Ezhilarasan, D. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.10.003 · Cited by 53
Curcumol alleviates liver fibrosis through inducing autophagy and ferroptosis in hepatic stellate cells
Zheng, Y., Zhao, T., Wang, J., Jiang, R., Huang, J., Li, W., & Wang, J. (2022) · The FASEB Journal · doi:10.1096/fj.202200933rr · Cited by 49
Intracellular Toxic AGEs (TAGE) Triggers Numerous Types of Cell Damage
Takeuchi, M., Sakai, A., Takata, T., Takino, J.-I., Koriyama, Y., Kikuchi, C., Furukawa, A., Nagamine, K., Hori, T., & Matsunaga, T. (2021) · Biomolecules · doi:10.3390/biom11030387 · Cited by 51
Mitochondrial Dynamics and Liver Cancer
Hernández‐Álvarez, M. I., & Antonio Zorzano, A. (2021) · Cancers · doi:10.3390/cancers13112571 · Cited by 50
The Bioactive Extract of Pinnigorgia sp. Induces Apoptosis of Hepatic Stellate Cells via ROS-ERK/JNK-Caspase-3 Signaling
Kuo, L.-M., Chen, P., Sung, P., Chang, Y., Ho, C.-T., Wu, Y., & Hwang, T. (2018) · Marine Drugs · doi:10.3390/md16010019 · Cited by 49
Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
Sircana, A., Paschetta, E., Saba, F., Molinaro, F., & Musso, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071745 · Cited by 46
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 48
Selonsertib Inhibits Liver Fibrosis via Downregulation of ASK1/ MAPK Pathway of Hepatic Stellate Cells
Yoon, Y., Fang, Z., Lee, J. E., Park, J. H., Ryu, J., Jung, K. H., & Hong, S. (2020) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.016 · Cited by 47
Gambogic acid attenuates liver fibrosis by inhibiting the PI3K/AKT and MAPK signaling pathways via inhibiting HSP90
Yu, Z., Jv, Y., Cai, L. F., Tian, X., Huo, X., Wang, C., Zhang, B., Sun, C., Ning, J., Feng, L., et al. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.03.028 · Cited by 45
Self-citation
Geniposide protected hepatocytes from acetaminophen hepatotoxicity by down-regulating CYP 2E1 expression and inhibiting TLR 4/NF-κB signaling pathway
Yang, S., Kuang, G., Jiang, R., Wu, S., Zeng, T., Wang, Y., Xu, F., Xiong, L., Gong, X., & Wan, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.010 · Cited by 45
Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3
Ji, D., Chen, G., Wang, J., Ji, S., Wu, X., Lu, X., Chen, J., & Li, J.-T. (2020) · Aging · doi:10.18632/aging.102705 · Cited by 45
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
Sabbadini, F., Bertolini, M., Matteis, S. D., Mangiameli, D., Contarelli, S., Pietrobono, S., & Melisi, D. (2021) · Cancers · doi:10.3390/cancers13163960 · Cited by 44
Gardeniae Fructus Attenuates Thioacetamide-Induced Liver Fibrosis in Mice via Both AMPK/SIRT1/NF-κB Pathway and Nrf2 Signaling
Shin, M.-R., Lee, J. A., Kim, M. J., Lee, S. H., Oh, M., Moon, J., Nam, J., Choi, H., Mun, Y., & Roh, S. (2021) · Antioxidants · doi:10.3390/antiox10111837 · Cited by 45
Advances in Understanding the Role of NRF2 in Liver Pathophysiology and Its Relationship with Hepatic-Specific Cyclooxygenase-2 Expression
Fuertes‐Agudo, M., Luque-Tévar, M., Cucarella, C., Martín‐Sanz, P., & Casado, M. (2023) · Antioxidants · doi:10.3390/antiox12081491 · Cited by 48
Common Bile Duct Ligation as Model for Secondary Biliary Cirrhosis
Campenhout, S. V., Vlierberghe, H. V., & Devisscher, L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9420-5_15 · Cited by 44
Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease
Salva-Pastor, N., Chávez-Tapia, N. C., Uribe, M., & Nuño‐Lámbarri, N. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105445 · Cited by 44
Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids
Wu, X., Jiang, D., Yang, Y. A., Li, S., & Ding, Q. (2023) · Cell Regeneration · doi:10.1186/s13619-022-00148-1 · Cited by 48
In Vitro Modeling of the Tumor Microenvironment in Tumor Organoids
Devarasetty, M., Forsythe, S. D., Shelkey, E., & Söker, S. (2020) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-020-00258-4 · Cited by 45
Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment
Zhu, B., Chan, S., Li, J., Li, K. S., Wu, H., Cui, K., & Chen, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.742382 · Cited by 47
Roseotoxin B alleviates cholestatic liver fibrosis through inhibiting PDGF-B/PDGFR-β pathway in hepatic stellate cells
Wang, X., Gao, Y., Yu, L., Huang, Y., Zhu, Y., lv, W., Wang, R., Gou, L., Cheng, C., Feng, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2575-0 · Cited by 42
Targeting the devil: Strategies against cancer-associated fibroblasts in colorectal cancer
Chen, Y., Liang, Z., & Lai, M. (2024) · Translational research · doi:10.1016/j.trsl.2024.04.003 · Cited by 44
Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population
Salva-Pastor, N., López-Sánchez, G. N., Chávez-Tapia, N. C., Audifred-Salomón, J. R., Niebla-Cárdenas, D., Estrada, R. T., Pereznuñez-Zamora, H., Vidaltamayo-Ramírez, R., Báez-Arellano, M. E., Uribe, M., et al. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.01.004 · Cited by 41
Targeting Activated Hepatic Stellate Cells Using Collagen-Binding Chitosan Nanoparticles for siRNA Delivery to Fibrotic Livers
Azzam, M., Elsafy, S., Abdelgelil, S. A., Weiskirchen, R., Asimakopoulou, A., Lorenzi, F. D., Lammers, T., Mansour, S., & Tammam, S. N. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060590 · Cited by 43
Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antifibrogenic activity
Jing, H., Ren, Y., Zhou, Y., Xu, M., Křížková, S., Heger, Z., Lü, Q., Wang, S., Liang, X., Adam, V., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.020 · Cited by 40
Deciphering Molecular Mechanisms of Carbon Tetrachloride- Induced Hepatotoxicity: A Brief Systematic Review
Fareed, M. M., Khalid, H., Khalid, S., & Shityakov, S. (2023) · Current Molecular Medicine · doi:10.2174/0115665240257603230919103539 · Cited by 45
Understanding fibrosis: Mechanisms, clinical implications, current therapies, and prospects for future interventions
Ku, J. C., Raiten, J., & Li, Y. (2024) · Biomedical Engineering Advances · doi:10.1016/j.bea.2024.100118 · Cited by 44
Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways
Yong, Q., Huang, C., Chen, B., An, J., Zheng, Y., Zhao, L., Peng, C., & Liu, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116952 · Cited by 40
Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
Yavuz, B. G., Pestana, R. C., Abugabal, Y. I., Krishnan, S., Chen, J., Hassan, M. M., Wolff, R. A., Rashid, A., Amin, H. M., & Kaseb, A. O. (2020) · Oncotarget · doi:10.18632/oncotarget.27532 · Cited by 40
Carcinogenesis and Metastasis in Liver: Cell Physiological Basis
Rossetto, A., Re, V. D., Steffan, A., Ravaioli, M., Miolo, G., Leone, P., Racanelli, V., Uzzau, A., Baccarani, U., & Cescon, M. (2019) · Cancers · doi:10.3390/cancers11111731 · Cited by 39
Cholesterol Induces Nrf-2- and HIF-1 α-Dependent Hepatocyte Proliferation and Liver Regeneration to Ameliorate Bile Acid Toxicity in Mouse Models of NASH and Fibrosis
Kaminsky-Kolesnikov, Y., Rauchbach, E., Abu-Halaka, D., Hahn, M., García-Ruiz, C., Fernandez-Checa, J. C., Madar, Z., & Tirosh, O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5393761 · Cited by 39
The regulatory role and mechanism of autophagy in energy metabolism-related hepatic fibrosis
Hou, L., Zhang, Y., Li, H., Wang, W., Huan, M., Zhou, S., & Zhang, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108117 · Cited by 39
Notoginsenoside R1, An Active Compound from Panax notoginseng , Inhibits Hepatic Stellate Cell Activation and Liver Fibrosis via MAPK Signaling Pathway
Gong, X., Shan, L., Cao, S., Li, K., Wu, Y., & Zhang, Q. (2022) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x22500197 · Cited by 37
Hepatic Stellate Cell- and Liver Microbiome-Specific Delivery System for Dihydrotanshinone I to Ameliorate Liver Fibrosis
Niu, X., Meng, Y., Cui, J., Li, R., Ding, X. Q., Niu, B., Chang, G., Xu, N., Li, G., Wang, Y., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c06626 · Cited by 40
Collagenase Type I and Probucol-Loaded Nanoparticles Penetrate the Extracellular Matrix to Target Hepatic Stellate Cells for Hepatic Fibrosis Therapy.
Wang, X., Zhang, W., Zeng, S., Wang, L.-D., & Wang, B. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.12.027 · Cited by 40
Mechanistic aspects of antifibrotic effects of honokiol in Con A-induced liver fibrosis in rats: Emphasis on TGF-β/SMAD/MAPK signaling pathways
Elfeky, M. G., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & El‐Demerdash, E. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117096 · Cited by 38
Modulation of the VEGF/AKT/eNOS signaling pathway to regulate liver angiogenesis to explore the anti-hepatic fibrosis mechanism of curcumol
Zheng, Y., Wang, J., Zhao, T., Wang, L., & Wang, J. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114480 · Cited by 38

Authors: Zhang, C.-Y., Yuan, W.-G., He, P., Lei, J.-H., & Wang, C.-X.
Affiliations: Huazhong University of Science and Technology (CN)
Venue: World Journal of Gastroenterology
Publisher: Baishideng Publishing Group Inc.
Published: 2016
Volume: 22
Issue: 48
Pages: 10512
ISSN: 1007-9327 (ISSN-L)
DOI: 10.3748/wjg.v22.i48.10512
PMC: PMC5192262
OpenAlex: W2565367159
Cited by: 594
References: 112
Citations by year: 2026: 37 · 2025: 70 · 2024: 75 · 2023: 80 · 2022: 84 · 2021: 88 · 2020: 60 · 2019: 59 · 2018: 24 · 2017: 15
FWCI: 4.07
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: World Journal of Gastroenterology (publishedVersion, cc-by-nc)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion, cc-by-nc)
PubMed (publishedVersion)
Funders: National Natural Science Foundation of China (81300251)
Topics: Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords: liver fibrosis, hepatic stellate cells, liver cirrhosis, hepatocellular carcinoma, antifibrotic therapy, fibrogenic factors, collagen synthesis, myofibroblasts, viral hepatitis, schistosomiasis, alcoholic liver disease, cell-cell crosstalk, therapeutic target
MeSH terms: Resveratrol, Ursolic Acid, Acetyl-CoA C-Acetyltransferase, Animals, Fatty Liver, Alcoholic, Humans, Interleukins, Liver Cirrhosis, Macrophages, Schistosomiasis, Stilbenes, Triterpenes, Ursodeoxycholic Acid, Virus Diseases, Signal Transduction, CD4-Positive T-Lymphocytes, Disease Progression, MicroRNAs, Intracellular Signaling Peptides and Proteins, T-Lymphocytes, Regulatory, Hepatic Stellate Cells, Molecular Targeted Therapy, LIM Domain Proteins, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks